evosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen - Levo vor HLM bei CABG

Charité - Universitätsmedizin Berlin0 个研究点开始时间: 2007年10月30日最近更新: 2013年6月3日

试验速览

暂无简介。

•Written informed consent by the patient to participate in the study (according to AMG §40 (1) 3b)
•Age older than 18 years
•Negative pregnancy testing or being postmenopausal for more than two years
•No participation in another clinical AMG trial
•Patients undergoing elective CABG-surgery with/without valve correction procedures
•Left ventricular ejection fraction equal or smaller than 30 %
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•A patient is commited to an institution because of an official or medical order (according to AMG §40 (1) 4)
•No informed written consent by the patient
•Participation in another clinical study
•ASA > III
•Severe oesophageal or upper airway disease
•Recent oesophageal or upper airway surgery
•Liver disease (Child B or C cirrhosis, akute disease, MILD Score > 17)
•Age < 18 ys.
•Unclear history of alcohol use disorder
•Neurological or psychiatric diseases
•Treatment with oral antidiabetics
•Presence of of an infection with HIV and symptoms of AIDS
•Clinical or anamnestic signs for the presence of an active Hepatitis B / C infection

发起方